Lyell Immunopharma, Inc. (LYEL) Ownership
LYEL ownership summary
as of October 18, 2026- Institutions
- 54.2% of shares outstanding
- Insiders
- 37.31% of shares outstanding
- Shares outstanding
- 24.5M
- Float
- 12.1M shares available to trade
- Short interest
- 6.02% 1.3M shares short
- Days to cover
- 9.40 short interest up 6.4% vs prior month
- Institutions 54.22%
- Insiders 37.31%
- Other investors 8.47%
LYEL top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | ARCH VENTURE CORP | 13.25% | 3.2M | $26.4M | — | June 30, 2026 |
| 2 | GSK PLC | 6.17% | 1.5M | $12.3M | — | June 30, 2026 |
| 3 | Vanguard Capital Management, LLC | 3.21% | 787K | $6.4M | +68,619 (+9.6%) | June 30, 2026 |
| 4 | Orland Properties Ltd | 3.08% | 755K | $6.1M | — | June 30, 2026 |
| 5 | BlackRock Inc | 2.96% | 724K | $5.9M | +532,522 (+277.6%) | June 30, 2026 |
| 6 | Almitas Capital LLC | 2.37% | 581K | $4.7M | +3,600 (+0.6%) | June 30, 2026 |
| 7 | Foresite Capital Management V, LLC | 1.94% | 476K | $3.9M | −692 (−0.1%) | June 30, 2026 |
| 8 | Millennium Management LLC | 1.50% | 367K | $3.0M | −91,432 (−19.9%) | June 30, 2026 |
| 9 | Opaleye Management Inc | 1.40% | 344K | $2.8M | +264,928 (+334.9%) | June 30, 2026 |
| 10 | venBio Partners LLC | 1.38% | 338K | $2.7M | — | June 30, 2026 |
| 11 | Geode Capital Management, LLC | 1.27% | 311K | $2.5M | +143,656 (+86.0%) | June 30, 2026 |
| 12 | Alphabet Inc | 1.20% | 293K | $2.4M | — | June 30, 2026 |
| 13 | State Street Corp | 0.76% | 185K | $1.5M | +112,800 (+155.5%) | June 30, 2026 |
| 14 | HSG Holding Ltd | 0.62% | 152K | $1.2M | — | June 30, 2026 |
| 15 | Renaissance Technologies Corp | 0.53% | 130K | $1.1M | +13,779 (+11.8%) | June 30, 2026 |
| 16 | Northern Trust Corp | 0.48% | 118K | $962,220 | +88,220 (+291.3%) | June 30, 2026 |
| 17 | Qube Research & Technologies | 0.45% | 111K | $897,512 | +55,421 (+100.6%) | June 30, 2026 |
| 18 | Charles Schwab Investment Management Inc | 0.44% | 108K | $873,468 | +21,599 (+25.1%) | June 30, 2026 |
| 19 | Marshall Wace Asset Management Ltd | 0.43% | 106K | $863,156 | −42,216 (−28.4%) | June 30, 2026 |
| 20 | Velan Capital Investment Management LP | 0.43% | 105K | $852,600 | +3,000 (+2.9%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 1.3M shares and 3 cut 134K.
LYEL top mutual fund and ETF holders
19 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.47% | 604K | $4.9M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 0.93% | 228K | $1.9M | −2,624 (−1.1%) | September 30, 2026 |
| 3 | Fidelity Small Cap Index | 0.42% | 104K | $840,964 | +889 (+0.9%) | July 31, 2026 |
| 4 | iShares Russell 2000 Value ETF | 0.31% | 77K | $624,241 | +116 (+0.2%) | September 30, 2026 |
| 5 | iShares Biotechnology ETF | 0.24% | 60K | $485,341 | −456 (−0.8%) | September 30, 2026 |
| 6 | Schwab US Small-Cap ETF™ | 0.23% | 56K | $457,724 | +36 (+0.1%) | September 30, 2026 |
| 7 | Vanguard Russell 2000 ETF | 0.22% | 54K | $439,609 | +1,080 (+2.0%) | August 31, 2026 |
| 8 | Fidelity Extended Market Index | 0.21% | 52K | $419,171 | −17,970 (−25.8%) | August 31, 2026 |
| 9 | Vanguard Health Care ETF | 0.12% | 28K | $231,331 | +120 (+0.4%) | August 31, 2026 |
| 10 | Northern Small Cap Value | 0.12% | 28K | $230,202 | +28,350 (0.0%) | June 30, 2026 |
| 11 | iShares Micro-Cap ETF | 0.11% | 27K | $218,233 | −185 (−0.7%) | September 30, 2026 |
| 12 | Fidelity Total Market Index | 0.11% | 26K | $209,577 | — | August 31, 2026 |
| 13 | EA Bridgeway Ultra-Small Company Mkt ETF | 0.10% | 25K | $205,095 | — | September 30, 2026 |
| 14 | Avantis US Small Cap Equity ETF | 0.10% | 24K | $194,799 | — | September 30, 2026 |
| 15 | Schwab Small Cap Index | 0.09% | 23K | $186,192 | — | August 31, 2026 |
| 16 | Fidelity Series Total Market Index | 0.09% | 21K | $174,312 | — | August 31, 2026 |
| 17 | iShares Russell 2000 Small-Cap Idx Instl | 0.07% | 18K | $142,823 | — | August 31, 2026 |
| 18 | iShares Nasdaq US Biotech ETF USD Acc | 0.07% | 18K | $142,238 | +148 (+0.9%) | September 30, 2026 |
| 19 | iShares Healthcare Innov ETF USD Acc | 0.07% | 17K | $134,662 | +65 (+0.4%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
LYEL insider transactions
latest 19| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-11 | Lynn Seely | Sell | $23.39 | 7,455 | $174,372 |
| 2026-02-11 | Stephen J Hill | Sell | $23.39 | 1,236 | $28,910 |
| 2026-02-11 | Gary K Lee | Sell | $23.39 | 1,671 | $39,085 |
| 2026-02-10 | Gary K Lee | Sell | $23.12 | 147 | $3,399 |
| 2026-02-10 | Lynn Seely | Sell | $23.12 | 438 | $10,127 |
| 2026-02-10 | Stephen J Hill | Sell | $23.12 | 109 | $2,520 |
| 2026-02-10 | Veronica Sanchez Bulis | Sell | $23.12 | 254 | $5,872 |
| 2025-11-10 | Stephen J Hill | Sell | $16.12 | 95 | $1,531 |
| 2025-11-10 | Veronica Sanchez Bulis | Sell | $16.10 | 239 | $3,848 |
| 2025-11-10 | Lynn Seely | Sell | $16.11 | 412 | $6,637 |
| 2025-11-10 | Gary K Lee | Sell | $16.16 | 138 | $2,230 |
| 2025-08-12 | Charles W Newton | Sell | $10.34 | 136 | $1,406 |
| 2025-08-12 | Gary K Lee | Sell | $10.34 | 136 | $1,406 |
| 2025-08-12 | Lynn Seely | Sell | $10.34 | 406 | $4,198 |
| 2025-08-12 | Stephen J Hill | Sell | $10.34 | 94 | $972 |
| 2025-08-11 | Charles W Newton | Sell | $10.53 | 131 | $1,379 |
| 2025-08-11 | Gary K Lee | Sell | $10.53 | 131 | $1,379 |
| 2025-08-11 | Lynn Seely | Sell | $10.53 | 391 | $4,117 |
| 2025-08-11 | Stephen J Hill | Sell | $10.53 | 91 | $958 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
LYEL shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns LYEL
Institutional investors own 54.2% of Lyell Immunopharma's shares and insiders 37.31%. The largest holder is ARCH VENTURE CORP with 13.25% of the shares (3.2M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 3 reduced their stake in the latest filings. Short interest is 6.02% of the float, or 9.40 days of average trading volume. The share count rose 38.6% since 2020.
Related: LYEL analyst forecast, LYEL key metrics. See the LYEL stock overview for the latest quote and news.
LYEL ownership FAQ
Who owns the most Lyell Immunopharma stock?
The largest shareholders of Lyell Immunopharma are ARCH VENTURE CORP (13.25%), GSK PLC (6.17%), Vanguard Capital Management, LLC (3.21%), Orland Properties Ltd (3.08%), BlackRock Inc (2.96%).
What percentage of Lyell Immunopharma is owned by institutions?
Institutions hold 54.2% of Lyell Immunopharma's shares outstanding; insiders hold 37.31%.
Which funds own Lyell Immunopharma?
The largest fund holders of Lyell Immunopharma are Vanguard MStar Total Stk Mkt Idx Invest (2.47%), iShares Russell 2000 ETF (0.93%), Fidelity Small Cap Index (0.42%), iShares Russell 2000 Value ETF (0.31%), iShares Biotechnology ETF (0.24%).
What is Lyell Immunopharma's short interest?
1.3M shares of Lyell Immunopharma were sold short, 6.02% of the float; at the average daily volume it would take 9.40 days to cover.
Are insiders buying or selling Lyell Immunopharma?
Of the latest 19 reported insider transactions in Lyell Immunopharma (since August 11, 2025), 0 were purchases and 19 were sales.
How many shares of Lyell Immunopharma are outstanding?
Lyell Immunopharma has 24.5M shares outstanding, of which 12.1M are in the public float.